Wu Jiao, Cui Ning, Li Zhongyu, Wu Yu, Hao Tengteng, Li Liusheng
Oncology Department of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Front Pharmacol. 2023 Apr 20;14:1099659. doi: 10.3389/fphar.2023.1099659. eCollection 2023.
Limited evidence suggests that elderly patients with advanced colorectal cancer (ACRC) may benefit from traditional Chinese medicine (TCM). This study investigated the efficacy and safety of TCM in old ACRC patients treated in the Oncology Department of Xiyuan Hospital between January 2012 and December 2021. The clinical characteristics of these patients were retrospectively reviewed. Their progression-free survival (PFS) and total duration of TCM therapy (TTCM) were analyzed using the Kaplan-Meier curve. Forty-eight patients (F:M 13:35) with a mean age of 78.75 ± 2.99 years (range, 75-87) met the inclusion criteria. There were 18 cases of rectal cancer and 30 of colon cancer. The median PFS was 4 months (range, 1-26; 95% CI 3.26-4.73). The median TTCM was 5.5 months (range, 1-50; 95% CI 1.76-8.24). Subgroup analysis revealed that PFS and TTCM were shorter in patients with bone metastases and an ECOG performance status score of 2-3 ( < 0.05). No hematological toxicity or serious adverse reactions occurred during the study period. This real-world study demonstrates that TCM may be a potentially beneficial therapy for old ACRC patients, including when the ECOG performance status score is 2-3.
有限的证据表明，老年晚期结直肠癌（ACRC）患者可能从中医（TCM）中获益。本研究调查了2012年1月至2021年12月期间在西苑医院肿瘤科接受治疗的老年ACRC患者使用中医的疗效和安全性。对这些患者的临床特征进行了回顾性分析。使用Kaplan-Meier曲线分析了他们的无进展生存期（PFS）和中医治疗总时长（TTCM）。48例患者（女性:男性为13:35），平均年龄为78.75±2.99岁（范围75 - 87岁）符合纳入标准。其中直肠癌18例，结肠癌30例。中位PFS为4个月（范围1 - 26个月；95%CI 3.26 - 4.73）。中位TTCM为5.5个月（范围1 - 50个月；95%CI 1.76 - 8.24）。亚组分析显示，骨转移患者和东部肿瘤协作组（ECOG）体能状态评分为2 - 3分的患者的PFS和TTCM较短（<0.05）。研究期间未发生血液学毒性或严重不良反应。这项真实世界研究表明，中医可能是老年ACRC患者的一种潜在有益治疗方法，包括ECOG体能状态评分为2 - 3分的患者。
